secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-045199
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma doses first three patients in Phase 2 glioblastoma trial; raises $4.5M
--------------------------------------------------------------------------------

- First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma; screening for additional patients ongoing.
- Paid off entire $4.3M Senior Secured Convertible Note ahead of March 2025 maturity.
- Completed $4.5M public offering; proceeds to fund clinical trials and working capital.
- Closed $790k convertible note/warrant offering, including $237.5k from CEO Anatoly Dritschilo.
- Cash balance $4.1M as of October 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224045199/0001493152-24-045199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224045199/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer